The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)

Moussa B. H. Youdim

Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases

Technion-Rappaport Family Faculty of Medicine




Name/email consistency: high



  • Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, Technion-Rappaport Family Faculty of Medicine, Haifa, Israel. 2000 - 2012
  • Department of Pharmacology, Bruce Rappaport Faculty of Medicine-Technion, Eve Topf and National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases Research, Efron St, Israel. 2004 - 2007
  • Technion-Faculty of Medicine, Eve Topf and NPF Neurodegenerative Disease Centers, Efron Street, Bat Galim, Israel. 2001 - 2006
  • Department of Pharmacology, Technion- Faculty of Medicine, P.O.B. 9697, 31096 Haifa, Israel. 2003
  • Technion, Faculty of Medicine, Eve Topf, Haifa, Israel. 1999 - 2002


  1. M30, a brain permeable multi target neurorestorative drug in post nigrostriatal dopamine neuron lesion of parkinsonism animal models. Youdim, M.B. Parkinsonism Relat. Disord. (2012) [Pubmed]
  2. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Youdim, M.B. Neurotox. Res (2008) [Pubmed]
  3. The copper chelator, D-penicillamine, does not attenuate MPTP induced dopamine depletion in mice. Youdim, M.B., Grünblatt, E., Mandel, S. J. Neural. Transm (2007) [Pubmed]
  4. Why should we use multifunctional neuroprotective and neurorestorative drugs for Parkinson's disease?. Youdim, M.B., Geldenhuys, W.J., Van der Schyf, C.J. Parkinsonism Relat. Disord. (2007) [Pubmed]
  5. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness. Youdim, M.B., Bakhle, Y.S. Br. J. Pharmacol. (2006) [Pubmed]
  6. The therapeutic potential of monoamine oxidase inhibitors. Youdim, M.B., Edmondson, D., Tipton, K.F. Nat. Rev. Neurosci. (2006) [Pubmed]
  7. The path from anti Parkinson drug selegiline and rasagiline to multifunctional neuroprotective anti Alzheimer drugs ladostigil and m30. Youdim, M.B. Current. Alzheimer. Research (2006) [Pubmed]
  8. Implications of co-morbidity for etiology and treatment of neurodegenerative diseases with multifunctional neuroprotective-neurorescue drugs; ladostigil. Youdim, M.B., Amit, T., Bar-Am, O., Weinreb, O., Yogev-Falach, M. Neurotox. Res (2006) [Pubmed]
  9. Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. Youdim, M.B., Bar Am, O., Yogev-Falach, M., Weinreb, O., Maruyama, W., Naoi, M., Amit, T. J. Neurosci. Res. (2005) [Pubmed]
  10. Bifunctional drug derivatives of MAO-B inhibitor rasagiline and iron chelator VK-28 as a more effective approach to treatment of brain ageing and ageing neurodegenerative diseases. Youdim, M.B., Fridkin, M., Zheng, H. Mech. Ageing Dev. (2005) [Pubmed]
  11. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Youdim, M.B., Buccafusco, J.J. Trends Pharmacol. Sci. (2005) [Pubmed]
  12. CNS Targets for multi-functional drugs in the treatment of Alzheimer's and Parkinson's diseases. Youdim, M.B., Buccafusco, J.J. J. Neural. Transm (2005) [Pubmed]
  13. Neuropharmacological, neuroprotective and amyloid precursor processing properties of selective MAO-B inhibitor antiparkinsonian drug, rasagiline. Youdim, M.B., Maruyama, W., Naoi, M. Drugs. Today (2005) [Pubmed]
  14. Therapeutic applications of selective and non-selective inhibitors of monoamine oxidase A and B that do not cause significant tyramine potentiation. Youdim, M.B., Weinstock, M. Neurotoxicology (2004) [Pubmed]
  15. Ironing iron out in Parkinson's disease and other neurodegenerative diseases with iron chelators: a lesson from 6-hydroxydopamine and iron chelators, desferal and VK-28. Youdim, M.B., Stephenson, G., Ben Shachar, D. Ann. N. Y. Acad. Sci. (2004) [Pubmed]
  16. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) dopaminergic neurotoxicity in mice by chronic lithium: involvements of Bcl-2 and Bax. Youdim, M.B., Arraf, Z. Neuropharmacology (2004) [Pubmed]
  17. A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease. Youdim, M.B., Riederer, P.F. Neurology (2004) [Pubmed]
  18. Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases. Youdim, M.B., Fridkin, M., Zheng, H. J. Neural. Transm (2004) [Pubmed]
  19. cDNA gene expression profile homology of antioxidants and their antiapoptotic and proapoptotic activities in human neuroblastoma cells. Weinreb, O., Mandel, S., Youdim, M.B. FASEB J. (2003) [Pubmed]
  20. Amyloid processing and signal transduction properties of antiparkinson-antialzheimer neuroprotective drugs rasagiline and TV3326. Youdim, M.B., Amit, T., Bar-Am, O., Weinstock, M., Yogev-Falach, M. Ann. N. Y. Acad. Sci. (2003) [Pubmed]
  21. What have we learnt from CDNA microarray gene expression studies about the role of iron in MPTP induced neurodegeneration and Parkinson's disease?. Youdim, M.B. J. Neural Transm. Suppl. (2003) [Pubmed]
  22. The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Youdim, M.B., Amit, T., Falach-Yogev, M., Bar Am, O., Maruyama, W., Naoi, M. Biochem. Pharmacol. (2003) [Pubmed]
  23. Rasagiline: an anti-Parkinson drug with neuroprotective activity. Youdim, M.B. Expert. Rev. Neurother (2003) [Pubmed]
  24. Novel neuroprotective anti-Alzheimer drugs with anti-depressant activity derived from the anti-Parkinson drug, rasagiline. Youdim, M.B., Weinstock, M. Mech. Ageing Dev. (2002) [Pubmed]
  25. The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Youdim, M.B., Wadia, A., Tatton, W., Weinstock, M. Ann. N. Y. Acad. Sci. (2001) [Pubmed]
  26. Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate]. Youdim, M.B., Weinstock, M. Cell. Mol. Neurobiol. (2001) [Pubmed]
  27. Iron chelating, antioxidant and cytoprotective properties of dopamine receptor agonist; apomorphine. Youdim, M.B., Gassen, M., Gross, A., Mandel, S., Grünblatt, E. J. Neural Transm. Suppl. (2000) [Pubmed]
  28. The pivotal role of iron in NF-kappa B activation and nigrostriatal dopaminergic neurodegeneration. Prospects for neuroprotection in Parkinson's disease with iron chelators. Youdim, M.B., Grünblatt, E., Mandel, S. Ann. N. Y. Acad. Sci. (1999) [Pubmed]
WikiGenes - Universities